Anixa Biosciences, Inc. Common Stock ANIX
HEALTHCARE · BIOTECHNOLOGYi
Market dataready · fetched 2026-11-13T00:48:07.042Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T22:10:04.969317015Z
FundamentalsAlpha Vantage · ready · quarter 2026-07-31 · fetched 2026-11-13T00:48:05.909489+00:00
Anixa Biosciences, Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | 2.50 | 379.9% | 47.1% | |||
| 30Δ | 2.71 | 360.7% | 43.4% | |||
| 35Δ | 4.83 | 233.0% | 88.4% | 2.91 | 341.4% | 39.7% |
| 40Δ | 4.49 | 235.1% | 79.2% | 3.11 | 322.1% | 36.1% |
| 45Δ | 4.16 | 237.3% | 70.0% | 3.31 | 302.9% | 32.4% |
| 50Δ | 3.82 | 239.4% | 60.8% | 3.51 | 283.6% | 28.7% |
| 55Δ | 3.48 | 241.6% | 51.7% | 3.71 | 264.3% | 25.1% |
| 60Δ | 3.15 | 243.8% | 42.5% | 3.92 | 245.1% | 21.4% |
| 65Δ | 2.81 | 245.9% | 33.3% | 4.12 | 225.8% | 17.7% |
| 70Δ | 4.32 | 206.5% | 14.0% | |||
| 75Δ | 4.52 | 187.3% | 10.4% | |||
| 80Δ | 4.72 | 168.0% | 6.7% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.50
- IV
- 379.9%
- B/E move
- 47.1%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.71
- IV
- 360.7%
- B/E move
- 43.4%
35Δ
- Pseudo strike
- 4.83
- IV
- 233.0%
- B/E move
- 88.4%
- Pseudo strike
- 2.91
- IV
- 341.4%
- B/E move
- 39.7%
40Δ
- Pseudo strike
- 4.49
- IV
- 235.1%
- B/E move
- 79.2%
- Pseudo strike
- 3.11
- IV
- 322.1%
- B/E move
- 36.1%
45Δ
- Pseudo strike
- 4.16
- IV
- 237.3%
- B/E move
- 70.0%
- Pseudo strike
- 3.31
- IV
- 302.9%
- B/E move
- 32.4%
50Δ
- Pseudo strike
- 3.82
- IV
- 239.4%
- B/E move
- 60.8%
- Pseudo strike
- 3.51
- IV
- 283.6%
- B/E move
- 28.7%
55Δ
- Pseudo strike
- 3.48
- IV
- 241.6%
- B/E move
- 51.7%
- Pseudo strike
- 3.71
- IV
- 264.3%
- B/E move
- 25.1%
60Δ
- Pseudo strike
- 3.15
- IV
- 243.8%
- B/E move
- 42.5%
- Pseudo strike
- 3.92
- IV
- 245.1%
- B/E move
- 21.4%
65Δ
- Pseudo strike
- 2.81
- IV
- 245.9%
- B/E move
- 33.3%
- Pseudo strike
- 4.12
- IV
- 225.8%
- B/E move
- 17.7%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.32
- IV
- 206.5%
- B/E move
- 14.0%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.52
- IV
- 187.3%
- B/E move
- 10.4%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.72
- IV
- 168.0%
- B/E move
- 6.7%
Options history
No recorded observations
Biotechnology
ANNX
Description unavailable
More →ANRO
Description unavailable
More →ANTX
Description unavailable
More →ARCT
Description unavailable
More →ARDX
Ardelyx, Inc., a biopharmaceutical company, develops and sells drugs for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company is…
More →ARGX
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The…
More →